RMC-9805 + RMC-6236 + cetuximab

RMC-9805 + RMC-6236 + cetuximab is an investigational **combination therapy** targeting solid tumors driven by KRAS G12D mutations, most notably pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer. - **RMC-9805** is a potent, oral, tri-complex small molecule inhibitor that is highly selective for the active, GTP-bound ("ON" state) KRAS G12D mutant, covalently binding and inhibiting its oncogenic signaling[3][4][5]. - **RMC-6236** is a pan-RAS(ON) inhibitor, also orally administered, targeting multiple activated RAS isoforms (KRAS, NRAS, HRAS), useful for KRAS or RAS mutant tumors[5]. - **Cetuximab** is a monoclonal antibody that binds to and inhibits the Epidermal Growth Factor Receptor (EGFR), blocking downstream mitogenic signaling. In preclinical and early clinical studies, combining RMC-9805 with RMC-6236 aims to provide deeper blockade of mutant RAS signaling; cetuximab adds further targeted inhibition in epithelial tumors such as colorectal cancer. This triple regimen is mainly under study for its safety, tolerability, and potential antitumor activity[6][5]. Developed and studied primarily by Revolution Medicines, this regimen has entered **Phase 1/2 trials**.